Victor Angles-Hermoza
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total. Reporting peaked in 2023 at $1,051 and has fallen 53.0% since, to $494 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$975
- Bayer$482
- Exact Sciences$261
- AstraZeneca$259
- AbbVie$226
- Lilly USA, LLC$222
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $975 |
| Bayer | 20 | $482 |
| Exact Sciences | 9 | $261 |
| AstraZeneca(2 entities) | 11 | $259 |
| AbbVie | 11 | $226 |
| Lilly USA, LLC | 14 | $222 |
| Amgen | 9 | $170 |
| Amarin Pharma, Inc. | 7 | $152 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $121 |
| Novartis | 6 | $115 |
| Merck | 6 | $106 |
| Boehringer Ingelheim | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| GSK | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Biogen | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Dexcom, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Pfizer | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Vistapharm, Inc. | 1 | $13 |
How this compares
$3,529 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 57 | $435 |
| Omeprazole | 11 | $277 |
| Atorvastatin Calcium | 32 | $203 |
| Azithromycin | 54 | $140 |
| Ibuprofen | 19 | $91 |
| Metformin Hcl | 14 | $80 |
| Hydrochlorothiazide | 13 | $63 |
| Cyclobenzaprine Hcl | 16 | $47 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.